Liquidia Corporation (NASDAQ:LQDA – Get Free Report) insider Rajeev Saggar sold 29,534 shares of Liquidia stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $76.84, for a total transaction of $2,269,392.56. Following the transaction, the insider directly owned 142,265 shares of the company’s stock, valued at approximately $10,931,642.60. This trade represents a 17.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Rajeev Saggar also recently made the following trade(s):
- On Wednesday, August 19th, Rajeev Saggar sold 50,000 shares of Liquidia stock. The stock was sold at an average price of $74.06, for a total transaction of $3,703,000.00.
- On Monday, July 13th, Rajeev Saggar sold 9,926 shares of Liquidia stock. The shares were sold at an average price of $71.51, for a total transaction of $709,808.26.
Liquidia Stock Down 5.7%
LQDA stock opened at $71.05 on Friday. Liquidia Corporation has a one year low of $21.15 and a one year high of $93.61. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 2.31. The firm’s fifty day moving average is $79.34 and its 200 day moving average is $56.13. The firm has a market cap of $6.36 billion, a PE ratio of 51.86 and a beta of 0.58.
Institutional Investors Weigh In On Liquidia
Institutional investors have recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Liquidia during the fourth quarter valued at approximately $25,000. NewEdge Advisors LLC acquired a new stake in shares of Liquidia in the second quarter worth approximately $25,000. Covestor Ltd boosted its stake in shares of Liquidia by 41.9% in the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after acquiring an additional 359 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of Liquidia by 281.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock worth $83,000 after purchasing an additional 4,927 shares in the last quarter. Finally, Globeflex Capital L P purchased a new stake in shares of Liquidia during the second quarter worth approximately $175,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of equities analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a research report on Friday, July 17th. Lifesci Capital cut Liquidia from an “outperform” rating to a “hold” rating and set a $90.00 price objective for the company. in a research report on Wednesday, August 12th. BTIG Research upped their target price on Liquidia from $109.00 to $111.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Bank of America increased their target price on Liquidia from $79.00 to $92.00 and gave the company a “neutral” rating in a research report on Thursday, August 13th. Finally, Needham & Company LLC lifted their price target on shares of Liquidia from $70.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $98.08.
Get Our Latest Research Report on Liquidia
Liquidia Company Profile
Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.
The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).
Read More
- Five stocks we like better than Liquidia
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.
